Geovax reports positive interim data from phase 2 clinical trial of geo-cm04s1 as a universal covid-19 vaccine booster

Results demonstrate potential protective immunity against multiple sars-cov-2 variants atlanta, ga, feb. 06, 2024 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced positive initial safety and immune response findings from its phase 2 clinical trial at one month following administration of its covid-19 vaccine, geo-cm04s1. the trial, evaluating geo-cm04s1 as a heterologous booster in 63 healthy adults who had previously received the pfizer or moderna mrna vaccine (clinicaltrials.gov identifier:  nct04639466 ), was fully enrolled at the end of sept 2023.
GOVX Ratings Summary
GOVX Quant Ranking